SGMT Sagimet Biosciences Inc.

NASDAQ
$9.24

Sagimet Biosciences Inc. (SGMT) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.5% since its last earnings release on August 11, 2026.

Sagimet Biosciences Beat Consensus Estimates
Tuesday, August 11, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.25)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.54

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Sagimet Biosciences Inc.

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.